A
Aqemia
Inventing new drugs at scale with generative AI and deep physics
Paris, France (office in London, UK)
70+
About Aqemia
Industry:
AI Drug Discovery
Founded:
2019
Founders:
Maximilien Levesque, Emmanuelle Martiano
Status:
Private
Funding & Growth
Total Raised:
$125M+
Stage:
Venture-backed
✓ Pros
- • Novel physics + generative-AI platform (no experimental training data required)
- • Well-funded ($125M+ raised)
- • Deep computational/physics research culture
- • Paris HQ with a London office
✗ Cons
- • Small, fast-scaling team (~70)
- • Drug pipeline still early
- • Crowded AI-drug-discovery field
🧬 Bioinformatics Focus
Aqemia pairs generative AI with a statistical-mechanics ("deep physics") engine that predicts binding affinity without relying on experimental training data, letting it screen billions of molecules per week to design small-molecule and RNA-targeted drug candidates.
The team spun out of the École Normale Supérieure in Paris in 2019 and runs its own discovery programs alongside partnerships with major pharmaceutical companies.